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Does Antihypertensive Drug Class Affect Day-to-Day Variability of
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Michihiro Satoh, PhD; Daisaku Yasui, MD, PhD; Jan A. Staessen, MD, PhD; Yutaka Imai, MD, PhD; on behalf of the Hypertensive Objective
Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) Study Investigators*
Background-—Recent literature suggests that blood pressure variability (BPV) predicts outcome beyond blood pressure level (BPL)
and that antihypertensive drug classes differentially influence BPV. We compared calcium channel blockers, angiotensin-converting
enzyme inhibitors, and angiotensin receptor blockade for effects on changes in self-measured home BPL and BPV and for their
prognostic significance in newly treated hypertensive patients.
Methods and Results-—We enrolled 2484 patients randomly allocated to first-line treatment with a calcium channel blocker
(n=833), an angiotensin-converting enzyme inhibitor (n=821), or angiotensin receptor blockade (n=830). Home blood pressures in
the morning and evening were measured for 5 days off treatment before randomization and for 5 days after 2 to 4 weeks of
randomized drug treatment. We assessed BPL and BPV changes as estimated by variability independent of the mean and compared
cardiovascular outcomes. Home BPL response in each group was significant (P≤0.0001) but small in the angiotensin-converting
enzyme inhibitor group (systolic/diastolic: 4.6/2.8 mm Hg) compared with the groups treated with a calcium channel blocker
(systolic/diastolic: 8.3/3.9 mm Hg) and angiotensin receptor blockade (systolic/diastolic: 8.2/4.5 mm Hg). In multivariable
adjusted analyses, changes in home variability independent of the mean did not differ among the 3 drug classes (P≥0.054). Evening
variability independent of the mean before treatment significantly predicted hard cardiovascular events independent of the
corresponding home BPL (P≤0.022), whereas BPV did not predict any cardiovascular outcome based on the morning measurement
(P≥0.056). Home BPV captured after monotherapy had no predictive power for cardiovascular outcome (P≥0.22).
Conclusions-—Self-measured home evening BPV estimated by variability independent of the mean had prognostic significance,
whereas antihypertensive drug classes had no significant impact on BPV changes. Home BPL should remain the primary focus for
risk stratification and treatment.
Clinical Trial Registration-—URL: http://www.umin.ac.jp/ctr/index.htm. Unique identifier: C000000137. ( J Am Heart Assoc.
2016;5:e002995 doi: 10.1161/JAHA.115.002995)
Key Words: antihypertensive drugs • blood pressure variability • cardiovascular outcomes • home blood pressure •morning and
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S elf-measurement of blood pressure at home is a moreaccurate prognosticator than conventionally measured
blood pressure because of the greater number of readings,
the minimization of the “white-coat effect,” and the reduction
of measurement error through use of automated blood
pressure monitors.1,2 Affordable and validated automated
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monitors for blood pressure self-measurement are readily
available. Similar to visit-to-visit variability in clinic blood
pressure,3,4 multiple home blood pressure measurements
provide information on day-to-day blood pressure variability in
the relatively controlled home environment.5,6 Although
subject to debate, some researchers proposed the idea that
antihypertensive drug classes differentially influence blood
pressure variability.7,8
The multicenter Hypertension Objective Treatment Based
on Measurement by Electrical Devices of Blood Pressure
(HOMED-BP) trial proved the feasibility of adjusting antihy-
pertensive drug treatment based on self-measured home
blood pressure.9,10 Based on accurate phenotype information,
we aimed to compare the effects on blood pressure level and
blood pressure variability and then to establish the prognostic
significance of calcium channel blockers (CCBs), angiotensin-
converting enzyme inhibitors (ACEIs), and angiotensin recep-
tor blockade (ARB). Home blood pressures, used in the
present study, were measured at baseline before treatment
and after initiation of CCB, ACEI, or ARB monotherapy.
Methods
Study Population
The HOMED-BP study was a multicenter clinical trial with a
PROBE (prospective, randomized, open-label, blinded end
point, evaluation)11 design. The HOMED-BP protocol complies
with the Declaration of Helsinki regarding investigation of
human subjects12 and is registered with the UMIN Clinical
Trial Registry (C000000137; http://www.umin.ac.jp/ctr). The
institutional review board of the Tohoku University Graduate
School of Medicine approved the study protocol, and all study
participants gave written informed consent.
In HOMED-BP,10,13 participants with mild to moderate
hypertension who were aged ≥40 years were recruited from
457 general practices throughout Japan. Participants were
Table 1. Detailed Information on Prescribed Medication
Among 3 Drug Classes
Drug Class and Generic Name Patients, n (%) Dosage, mg (%)
Calcium channel blocker 833
Amlodipine 439 (52.7) 5 (52.6)
Benidipine 183 (22.0) 4 (59.0)
Barnidipine 65 (7.8) 10 (38.5)
Azelnidipine 50 (6.0) 8 (56.0)
Cilnidipine 39 (4.7) 10 (33.3)
Others 57 (6.8) N/A
Angiotensin-converting enzyme
inhibitor
821
Imidapril 285 (34.7) 5 (71.6)
Perindopril 193 (23.5) 4 (51.8)
Enalapril 108 (13.2) 5 (76.9)
Quinapril 87 (10.6) 10 (52.9)
Temocapril 55 (6.7) 2 (78.2)
Others 93 (11.3) N/A
Angiotensin receptor blocker 830
Candesartan 292 (35.2) 4 (45.9)
Valsartan 232 (28.0) 80 (48.3)
Losartan 128 (15.4) 50 (56.3)
Telmisartan 104 (12.5) 40 (60.6)
Olmesartan 71 (8.6) 20 (50.7)
Irbesartan 3 (0.4) 100 (100)
N/A indicates not available.
↑↑↑↑ ↑↑ ↑↑↑↑
Off treatment Antihypertensive medication using CCB, ACEI, or ARB
≥14 days 10–28 days
RandomizationRegistration
Morning and evening 
home blood pressure
at baseline
Morning and evening 
home blood pressure
after the monotherapy
Figure 1. Time course of home blood pressure measurement before and after randomization. During the study period, morning blood
pressure was measured in a sitting position once every morning after ≥2 minutes of rest and within 1 hour of awakening, before
breakfast, and before taking antihypertensive medication, if patients were taking antihypertensive medication. Evening blood pressure
was measured in a sitting position once every evening just before going to bed and after ≥2 minutes of rest. Data on home blood
pressure values for, in principle, 5 days before randomization and for 5 days after 10 to 28 days of randomized drug treatment were
used for the calculation; patients with 3 to 4 days of home blood pressure data in each interval were also included. ACEI indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockade; CCB, calcium channel blocker.
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both treatment-na€ıve and previously treated patients whose
antihypertensive drug treatment could be discontinued for at
least 2 weeks. Off treatment, participants had to maintain a
self-measured morning home blood pressure of 135 to
179 mm Hg systolic or 85 to 119 mm Hg diastolic. Eligible
patients had no contraindication for being administered a
CCB, an ACEI, or ARB. In a 293 design, 3518 eligible patients
were randomized to usual control (ranging from 125 to
134 mm Hg systolic and from 80 to 84 mm Hg diastolic) or
tight control (<125 mm Hg systolic and 80 mm Hg diastolic)
of morning home blood pressure and to initiation of antihy-
pertensive drug treatment with a CCB, an ACEI, or ARB. The
first patient was randomized on June 6, 2001, and the last
patient was randomized on October 7, 2009. The primary
outcome of HOMED-BP study was published based on the
dataset with follow-up until April 30, 2010.10 Moreover, the
HOMED-BP management committee decided to continue the
operation of the HOMED-BP system until the end of 2012;
Table 2. Baseline Characteristics of 2484 Patients by Antihypertensive Drug Classes
Characteristic CCB ACEI ARB
Patients, n 833 821 830
Women 424 (50.9) 420 (51.2) 413 (49.8)
Current smoking 172 (20.6) 156 (19.0) 179 (21.6)
Drinking alcohol 394 (47.3) 386 (47.0) 404 (48.7)
Diabetes 123 (14.8) 132 (16.1) 125 (15.1)
Hypercholesterolemia 434 (52.1) 412 (50.2) 433 (52.3)
Previous cardiovascular diseases 18 (2.2) 21 (2.6) 28 (3.4)
Tight control group 433 (52.0) 393 (47.9) 425 (51.2)
Mean characteristic (SD)
Age, y 59.8 (10.0) 59.9 (9.7) 60.1 (9.7)
Body mass index, kg/m2 24.2 (3.2) 24.5 (3.5) 24.4 (3.2)
Fasting plasma glucose, mmol/L 5.84 (1.70) 5.85 (1.68) 5.79 (1.67)
Total serum cholesterol, mmol/L 5.42 (0.92) 5.45 (0.88) 5.49 (0.88)
Clinic systolic blood pressure, mm Hg 154.8 (17.8) 153.6 (17.1) 154 (16.9)
Clinic diastolic blood pressure, mm Hg 90.4 (12.2) 89.7 (12) 89.8 (11.8)
Home blood pressure, mm Hg
Morning systolic 151.6 (12.5) 151.3 (12.2) 150.8 (12.2)
Morning diastolic 89.9 (9.7) 89.6 (10.1) 89.3 (10.4)
Evening systolic 144.1 (15.3) 143.5 (15.0) 143.6 (15.3)
Evening diastolic 82.8 (10.6) 82.6 (10.7) 82.3 (11.2)
Home VIM, unit
Morning systolic 8.78 (4.05) 9.39 (4.37) 9.30 (4.38)
Morning diastolic 5.07 (2.44) 5.05 (2.60) 5.24 (2.72)
Evening systolic 10.71 (4.70) 10.72 (4.80) 11.03 (5.26)
Evening diastolic 6.37 (2.98) 6.44 (3.09) 6.54 (3.12)
Home ARV, mm Hg
Morning systolic 10.02 (5.03) 10.90 (5.90) 10.64 (5.57)
Morning diastolic 5.78 (3.05) 5.74 (3.18) 6.08 (3.50)
Evening systolic 12.65 (6.33) 12.62 (6.55) 12.88 (6.65)
Evening diastolic 7.50 (4.05) 7.68 (4.14) 7.63 (4.13)
Values are number of participants (%) or arithmetic mean (SD). Tight control group indicates patients who were allocated to tight control (<125 mm Hg systolic and 80 mm Hg diastolic) of
morning home blood pressure. Diabetes mellitus was defined as fasting plasma glucose of ≥7.0 mmol/L (≥126 mg/dL), HbA1c of ≥6.5%, or treatment with oral antidiabetic drugs or
insulin. Hypercholesterolemia was defined as total serum cholesterol of ≥5.69 mmol/L (≥220 mg/dL), a history of hypercholesterolemia, or taking lipid-lowering drugs. Baseline
characteristics did not differ between randomized groups (P≥0.10) with the exception of home VIM and ARV calculated by morning systolic measurements (P=0.0093 and P=0.022,
respectively). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockade; ARV, average real variability; CCB, calcium channel blocker; VIM, variability
independent of the mean.
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therefore, we collected blood pressure data and ascertained
outcomes until December 31, 2012.
Of the 3518 randomized patients, we excluded 1034 from
analysis because they had obtained <3 morning or evening
readings at baseline (n=303) or after monotherapy with the
first-line drug (n=697) or because they did not actually receive
an antihypertensive drug or were treated with ≥2 drug classes
simultaneously (n=34). A total of 2484 participants were
analyzed statistically.
Blood Pressure Measurement and Collection
Patients received spoken and written instructions on blood
pressure self-measurement and use of the validated14 oscil-
lometric Omron HEM-747IC-N monitors (Omron Healthcare
Co., Ltd.). The monitor stores up to 350 blood pressure and
heart rate readings in memory. The home blood pressure used
for determining eligibility and treatment adjustments at each
visit was the average of the morning readings available over
the 5 days immediately preceding the visit. Patients were
asked to measure blood pressure in the sitting position once
every morning throughout the study period after ≥2 minutes
of rest. They had to obtain these measurements within 1 hour
of awakening, before breakfast, and before taking antihyper-
tensive medication. They were also asked to measure blood
pressure once every evening throughout the study period just
before going to bed. The clinic blood pressure was also
measured by practitioners twice consecutively at each visit
using the validated15 oscillometric Omron HEM-907IT device
(Omron Healthcare Co., Ltd.) after patients had ≥2 minutes of
Table 3. Baseline Characteristics of Participants by Distribution of Overall Systolic VIM in the Morning
Characteristic Categories of Systolic VIM in the Morning P Value
Limits, U 0.84 to 6.16 6.16 to 8.42 8.42 to 11.3 11.3 to 37.4
Participants, n (%)
All participants in category 621 620 622 621
Women 294 (47.3) 307 (49.5) 315 (50.6) 341 (54.9)† 0.056
Current smoking 136 (21.9) 130 (21.0) 112 (18.0) 129 (20.8) 0.36
Drinking alcohol 303 (48.8) 306 (49.4) 290 (46.6) 285 (45.9) 0.56
Diabetes 88 (14.2) 105 (16.9) 91 (14.6) 96 (15.5) 0.55
Hypercholesterolemia 314 (50.6) 307 (49.5) 331 (53.2) 327 (52.7) 0.52
Previous cardiovascular diseases 14 (2.3) 11 (1.8) 15 (2.4) 27 (4.3) 0.028
Mean (SD) of characteristic
Age, y 58.8 (9.8) 59.7 (9.7) 59.9 (9.5) 61.4 (9.9)† <0.0001
Body mass index, kg/m2 24.5 (3.2) 24.6 (3.4) 24.5 (3.4) 23.8 (3.3)† 0.0002
Fasting plasma glucose, mmol/L 5.81 (1.71) 5.83 (1.64) 5.76 (1.51) 5.92 (1.85) 0.85
Total serum cholesterol, mmol/L 5.45 (0.90) 5.42 (0.86) 5.48 (0.88) 5.47 (0.93) 0.60
Blood pressure, mm Hg
Clinic systolic 154.2 (16.6) 153.7 (17.6) 153.7 (17.1) 154.8 (17.9) 0.60
Clinic diastolic 91.1 (11.5) 90.3 (12.0) 89.4 (12.1) 89.1 (12.3) 0.0032
Home morning systolic 151.9 (12.6) 150.7 (12.5) 150.9 (12.3) 151.4 (12.0) 0.32
Home morning diastolic 90.9 (9.8) 89.5 (10.0)* 89.7 (10.0) 88.3 (10.2)* 0.0002
Home evening systolic 144.5 (15.8) 142.4 (14.1)* 143.3 (14.6) 144.7 (16.2) 0.11
Home evening diastolic 83.6 (10.8) 81.7 (10.5)† 82.5 (11.0) 82.5 (11.1) 0.036
Home heart rate, beats per minute
Morning 68.3 (9.4) 68.2 (8.9) 68.7 (9.2) 69.1 (9.5) 0.28
Evening 72.9 (9.9) 73.2 (9.9) 72.9 (10.1) 72.5 (9.3) 0.66
Values are number of participants (%) or arithmetic mean (SD). VIM is based on self-measurement in the morning on up to 5 days (average 4.95 day) within 1 hour after awakening. Body
mass index, glucose, and cholesterol level were unavailable in 53, 215, and 81 patients, respectively. P denotes the significance of the linear trend across categories of systolic blood
pressure level. VIM indicates variability independent of the mean.
*P<0.05, significance of the difference with the adjacent lower fourth.
†P<0.01, significance of the difference with the adjacent lower fourth.
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rest in the sitting position. The clinic blood pressure was the
average of these 2 readings. At each visit, the central server
at Tohoku University received the home and clinic blood
pressure data from local practices and immediately displayed
these data on the screen of the local computer, along with
advice for treatment adjustment based on a computerized
algorithm, as described elsewhere.10,13 A particular drug was
also randomly displayed for doctors’ reference; however,
doctors were allowed to choose any antihypertensive drug
agents within each drug class based on the condition of the
patient, the adopted drug at each clinic, or their own
judgment, as shown in Table 1.
In the present study, data on home blood pressure values
for, in principle, 5 days before randomization and 5 days after
10 to 28 days of randomized drug treatment were used to
calculate level and variability at baseline and after monother-
apy, respectively (Figure 1).16 We used this time window
because (1) the home blood pressure used for determining
eligibility and treatment adjustments at each visit in the
HOMED-BP study was the average of the morning readings
available over 5 days immediately preceding the visit,10,13 (2)
the clinical investigators followed the study participants at
intervals of 2 to 4 weeks in general practice and 4 to
8 weeks at hospital outpatient clinics, and (3) the time intervals
needed to attain the maximum antihypertensive effects are
reported to be9 to 23 days.17 Averaged follow-up days were
calculated as the mean of 5 days of home blood pressure
measurements. Patients with home blood pressure data on 3 to
4 days in each interval were also included in the present study,
for which there was ≥4.80 average measurement days.
Table 4. Baseline Characteristics of Participants by Distribution of Overall Systolic VIM in the Evening
Characteristic Categories of Systolic VIM in the Evening P Value
Limits, units 0.99 to 7.44 7.44 to 10.1 10.1 to 13.5 13.5 to 42.0
Number of participants (%)
All participants in category 621 621 621 621
Women 281 (45.2) 320 (51.5)* 328 (52.8) 328 (52.8) 0.021
Current smoking 134 (21.6) 127 (20.5) 116 (18.7) 130 (20.9) 0.62
Drinking alcohol 291 (46.9) 289 (46.5) 287 (46.2) 317 (51.0) 0.28
Diabetes 92 (14.8) 106 (17.1) 90 (14.5) 92 (14.8) 0.56
Hypercholesterolemia 311 (50.1) 323 (52.0) 326 (52.5) 319 (51.4) 0.85
Previous cardiovascular diseases 16 (2.6) 18 (2.9) 14 (2.3) 19 (3.1) 0.82
Mean (SD) of characteristic
Age, y 58.2 (10.0) 59.4 (9.8)* 60.2 (9.6) 61.8 (9.4)† <0.0001
Body mass index, kg/m2 24.6 (3.4) 24.4 (3.4) 24.3 (3.3) 24.1 (3.2) 0.20
Fasting plasma glucose, mmol/L 5.74 (1.45) 5.88 (1.64) 5.91 (2.00) 5.79 (1.58) 0.33
Total serum cholesterol, mmol/L 5.46 (0.90) 5.45 (0.90) 5.47 (0.85) 5.43 (0.93) 0.88
Blood pressure, mm Hg
Clinic systolic 154.2 (17.1) 154.6 (16.9) 153.8 (16.9) 154.0 (18.3) 0.79
Clinic diastolic 90.7 (11.6) 90.9 (12.2) 89.9 (12.1) 88.5 (12.1)* 0.0023
Home morning systolic 150.0 (12.1) 150.5 (12.4) 150.9 (12.0) 153.4 (12.6)‡ <0.0001
Home morning diastolic 90.2 (9.6) 89.6 (10.1) 89.4 (10.0) 89.2 (10.5) 0.28
Home evening systolic 144.0 (15.1) 143.7 (15.2) 143.5 (15.5) 143.9 (15.0) 0.83
Home evening diastolic 83.7 (10.9) 83.0 (10.8) 82.4 (10.9) 81.1 (10.7)* 0.0004
Home heart rate, beat per minute
Morning 68.4 (9.2) 69.1 (9.5) 68.3 (9.0) 68.4 (9.4) 0.71
Evening 72.8 (9.8) 72.9 (9.5) 73.0 (10.0) 72.8 (10.0) 0.98
Values are number of participants (%) or arithmetic mean (SD). VIM is based on self-measurement in the evening on up to 5 days (average 4.93 days) just before going to bed. Body mass
index, glucose, and cholesterol level were unavailable in 53, 215, and 81 patients, respectively. P denotes the significance of the linear trend across categories of systolic blood pressure
level. VIM indicates variability independent of the mean.
*P<0.05, significance of the difference with the adjacent lower fourth.
†P<0.01, significance of the difference with the adjacent lower fourth.
‡P<0.001, significance of the difference with the adjacent lower fourth.
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Definition of Diseases and Events
We coded end points according to the International Classi-
fication of Diseases, 10th Revision (ICD-10). In the current
study, the primary hard end point was a composite of
cardiovascular death (ICD-10 codes I00–I99), nonfatal
myocardial infarction (I21), and nonfatal stroke (I60, I61,
and I63).9,10 The broader composite cardiovascular end point
encompassed the hard end point plus transient ischemic
attack (G45), angina pectoris (I20), coronary atherosclerosis
(I70), and fatal and nonfatal heart failure (I50).9,10 The end
point committee, which was unaware of patients’ randomiza-
tion, adjudicated all events. We used the outcome results
considering only the first event in individual patients.
Body mass index was calculated as body weight in kilograms
divided by height in meters squared. Diabetes mellitus was
determined by fasting plasma glucose ≥7.0 mmol/L
(≥126 mg/dL), HbA1c ≥6.5%,18 or treatment with antidiabetic
agents. Hypercholesterolemia was determined by total choles-
terol of ≥5.69 mmol/L (≥220 mg/dL), by a documented
history of hypercholesterolemia, or by taking lipid-lowering
drug treatment. We used the World Health Organization’s
defined daily doses19 (2011 version) to quantify the use of
antihypertensive drugs in each group at each visit.
Statistical Analysis
For database management and statistical analysis, we used SAS
software, version 9.4 (SAS Institute Inc). Statistical significance
was a < 0.05 on 2-sided tests. All data are expressed as
meanSDunless otherwise stated.We analyzed themorning and
evening blood pressures separately because previous studies
showed that they have different prognostic meanings.5,20
The within-participant blood pressure variability was repre-
sented by variability independent of the mean (VIM),3,5 which is
the standard deviation divided by the mean to the powerx. The
power x is obtained by fitting a curve through a plot of SD against
mean using themodel SD=axmeanx, where xwas derived by non-
linear regression analysis as implemented in the PROC NLIN
procedure of the SAS package. We also used average real
variability (ARV) calculated by the average of the absolute
differences between consecutive day blood pressure measure-
ments.21,22 We further computed blood pressure variability from
the standard deviation and the coefficient of variation.
For comparison of means and proportions, we applied the
Kruskal–Wallis test and the chi-square statistic, respectively.
We analyzed the difference among groups according to the
per-protocol analysis on first-line drug prescription to clarify
the antihypertensive drug effect on blood pressure level and
Table 5. Reduction of Blood Pressure Level and Variability After the Monotherapy in 3 Drug Classes Among 2484 Patients With ≥3
Measurements in Both Morning and Evening Home Blood Pressure
Characteristic
Calcium Channel
Blocker
Angiotensin-Converting
Enzyme Inhibitor
Angiotensin Receptor
Blocker
Crude
P Value
Adjusted
P Value
Average follow-up days 25.0 (14.0–26.0) 24.4 (12.7–26.0) 25.2 (15.0–26.0) 0.0022 N/A
Defined daily doses, U 0.85 (0.38) 0.64 (0.36) 0.77 (0.32) <0.0001 N/A
D Home blood pressure, mm Hg
Morning systolic 8.3 (10.7) 4.6 (10.6) 8.2 (11.0) <0.0001 <0.0001
Morning diastolic 3.9 (6.2) 2.8 (5.8) 4.5 (6.2) <0.0001 <0.0001
Evening systolic 9.4 (11.7) 7.0 (11.7) 9.7 (12.6) <0.0001 <0.0001
Evening diastolic 4.5 (6.7) 4.0 (6.7) 5.0 (7.5) 0.016 0.0021
D Home VIM, U
Morning systolic 0.12 (5.17) 0.20 (5.72) 0.25 (5.56) 0.86 0.057
Morning diastolic 0.14 (3.05) 0.09 (3.25) 0.02 (3.12) 0.16 0.054
Evening systolic 0.69 (5.95) 0.39 (6.06) 0.49 (6.14) 0.48 0.12
Evening diastolic 0.29 (3.70) 0.09 (3.72) 0.19 (3.64) 0.34 0.12
D Home ARV, mm Hg
Morning systolic 0.08 (6.62) 0.19 (7.67) 0.42 (7.08) 0.34 0.091
Morning diastolic 0.21 (3.87) 0.27 (4.17) 0.03 (4.14) 0.050 0.012
Evening systolic 0.76 (8.28) 0.35 (8.48) 0.46 (8.04) 0.42 0.24
Evening diastolic 0.33 (5.04) 0.16 (5.12) 0.15 (5.12) 0.80 0.16
Values are arithmetic mean (SD) except averaged follow-up days asmedian (interquartile range). Crude P denotes the significance of the difference among drug classes, and adjusted P displays
the significance which accounts for sex, age, bodymass index, corresponding blood pressure level or variability and heart rate at baseline, current smoking and drinking, hypercholesterolemia,
diabetes mellitus, history of cardiovascular disease, and defined daily doses. ARV indicates average real variability; N/A, not available; VIM, variability independent of the mean.
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variability. Changes in blood pressure from baseline to the
monotherapy period were tested by analysis of covariance,
which accounts for sex, age, body mass index, corresponding
blood pressure level or variability and heart rate at baseline,
current smoking and drinking, hypercholesterolemia, diabetes
mellitus, history of cardiovascular disease, and defined daily
doses after monotherapy. In line with the small differences in
home blood pressure, the risks of outcomes were similar in
the randomized groups10; therefore, we pooled all participants
for the survival analysis. We applied Cox regression to
compute hazard ratios (HRs) that expressed the change in risk
associated with a 1-SD increase in mean blood pressure or
variability. Covariables were sex, age, body mass index,
corresponding heart rate, current smoking and drinking,
hypercholesterolemia, diabetes mellitus, history of cardiovas-
cular disease, and antihypertensive drug classes. For analyz-
ing the risk of hard and broader cardiovascular events, we
used the competing risk model by Fine and Gray to account
for competing noncardiovascular death.23
Results
Baseline Characteristics
Of 2484 patients, 1257 (50.6%) were women, 507 (20.4%) were
current smokers, 1184 (47.7%) used alcohol, 380 (15.3%) had
diabetes, 1279 (51.5%) were hypercholesterolemia, and 67
(2.7%) had a history of cardiovascular disease. Age and body
mass index averaged 59.99.8 years and 24.33.3 kg/m2,
respectively. For all participants, the clinic blood pressure
averaged 154.117.3 mm Hg systolic and 90.012.0 dias-
tolic. The corresponding home systolic and diastolic blood
pressure levels were 151.212.3 and 89.610.0 mm Hg,
respectively, in the morning and 143.715.2 and
82.510.8 mm Hg, respectively, in the evening.
Table 2 lists the baseline characteristics by the initial
antihypertensive drug classes. No significant differences in
level and variability were observed among the 3 categories
(P≥0.10) except for VIM and ARV derived frommorning systolic
Table 6. SD and Coefficient of Variation of Home Blood Pressure at Baseline and After the Monotherapy Among 3 Drug Classes
Characteristic
Calcium Channel
Blocker
Angiotensin-
Converting
Enzyme Inhibitor
Angiotensin
Receptor Blocker Crude P Value
Adjusted
P Value
At baseline
SD, mm Hg
Morning systolic 8.80 (4.12) 9.40 (4.52) 9.27 (4.43) 0.019 0.0009
Morning diastolic 5.07 (2.45) 5.04 (2.58) 5.22 (2.70) 0.32 0.28
Evening systolic 10.71 (4.75) 10.71 (4.84) 11.01 (5.25) 0.62 0.26
Evening diastolic 6.38 (3.04) 6.42 (3.13) 6.52 (3.12) 0.66 0.31
Coefficient of variation, %
Morning systolic 5.81 (2.68) 6.21 (2.89) 6.16 (2.90) 0.0090 0.0017
Morning diastolic 5.68 (2.77) 5.69 (3.06) 5.91 (3.18) 0.27 0.21
Evening systolic 7.48 (3.31) 7.50 (3.37) 7.72 (3.74) 0.68 0.25
Evening diastolic 7.75 (3.63) 7.85 (3.80) 8.01 (3.92) 0.55 0.21
After monotherapy
D SD, mm Hg
Morning systolic 0.19 (5.17) 0.09 (5.78) 0.34 (5.48) 0.80 0.0084
Morning diastolic 0.15 (3.06) 0.12 (3.25) 0.01 (3.11) 0.11 0.060
Evening systolic 0.72 (6.05) 0.31 (6.11) 0.54 (6.19) 0.32 0.085
Evening diastolic 0.29 (3.76) 0.06 (3.74) 0.21 (3.64) 0.31 0.11
D Coefficient of variation, %
Morning systolic 0.21 (3.51) 0.15 (3.89) 0.15 (3.79) 0.81 0.078
Morning diastolic 0.08 (3.50) 0.31 (3.82) 0.28 (3.64) 0.18 0.043
Evening systolic 0.05 (4.28) 0.15 (4.38) 0.10 (4.45) 0.50 0.12
Evening diastolic 0.05 (4.61) 0.30 (4.67) 0.17 (4.62) 0.35 0.12
Values are arithmetic mean (SD). Crude P denotes the significance of the difference among drug classes, and adjusted P displays the significance which accounts for sex, age, body mass
index, corresponding blood pressure level, variability, and heart rate at baseline, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of cardiovascular disease,
and defined daily doses.
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blood pressure measurements (P=0.0093 and P=0.022,
respectively). Tables 3 and 4 list the baseline characteristics
by quartiles of VIM based on systolic blood pressure in the
morning and evening, respectively. The average morning and
evening systolic blood pressures were similar across the
corresponding VIM quartiles (P≥0.32), whereas age increased
by VIM category increment (P<0.0001).
Blood Pressure Level and Variability at Baseline
and After Monotherapy
Home blood pressure level and VIM measured after the
monotherapy in 3 antihypertensive drug classes are shown in
Table 5. At a median of 25.0 days (interquartile range 13.6–
26.0 days) after initiation of monotherapy, reduction of blood
Table 7. Baseline Blood Pressure Level and Variability and Reduction of These Indexes After Monotherapy Among Patients With
Amlodipine or Other CCB
Characteristic Amlodipine (n=439) Other CCB (n=394) Crude P Value Adjusted P Value
Baseline measurement
Home blood pressure, mm Hg
Morning systolic 152.9 (12.3) 150.1 (12.7) 0.0004 <0.0001
Morning diastolic 90.8 (9.6) 88.9 (9.7) 0.0016 0.0001
Evening systolic 145.1 (15.0) 143.0 (15.6) 0.058 0.0023
Evening diastolic 83.5 (10.6) 82.0 (10.7) 0.039 0.0061
Home VIM, U
Morning systolic 8.67 (4.24) 8.90 (3.82) 0.16 0.39
Morning diastolic 5.05 (2.43) 5.09 (2.45) 0.72 0.036
Evening systolic 10.52 (4.47) 10.92 (4.95) 0.33 <0.0001
Evening diastolic 6.34 (2.74) 6.42 (3.24) 0.77 <0.0001
Home ARV, mm Hg
Morning systolic 10.04 (5.26) 9.99 (4.77) 0.83 0.090
Morning diastolic 5.75 (3.03) 5.81 (3.07) 0.68 0.0053
Evening systolic 12.48 (5.93) 12.84 (6.75) 0.80 0.0006
Evening diastolic 7.46 (3.69) 7.55 (4.42) 0.54 <0.0001
After the monotherapy
D Home blood pressure, mm Hg
Morning systolic 10.24 (10.63) 6.03 (10.26) <0.0001 <0.0001
Morning diastolic 5.00 (6.27) 2.67 (5.78) <0.0001 <0.0001
Evening systolic 11.27 (11.75) 7.36 (11.27) <0.0001 <0.0001
Evening diastolic 5.39 (6.61) 3.52 (6.69) <0.0001 <0.0001
D Home VIM, U
Morning systolic 0.35 (5.18) 0.14 (5.16) 0.30 0.018
Morning diastolic 0.23 (2.90) 0.05 (3.21) 0.54 0.29
Evening systolic 0.52 (5.90) 0.89 (6.01) 0.80 0.63
Evening diastolic 0.27 (3.60) 0.32 (3.82) 0.92 0.92
D Home ARV, mm Hg
Morning systolic 0.44 (6.63) 0.65 (6.56) 0.035 0.0023
Morning diastolic 0.32 (3.74) 0.09 (4.01) 0.62 0.19
Evening systolic 0.69 (8.11) 0.84 (8.47) 0.68 0.89
Evening diastolic 0.37 (4.74) 0.28 (5.35) 0.51 0.51
Values are arithmetic mean (SD). Crude P denotes the significance of the difference between amlodipine and other CCBs, and adjusted P displays the significance which accounts for sex,
age, body mass index, corresponding blood pressure level (for VIM and ARV) or variability (for level) at baseline, corresponding heart rate at baseline, current smoking and drinking,
hypercholesterolemia, diabetes mellitus, history of cardiovascular disease, and defined daily doses. ARV indicates average real variability; CCB, calcium channel blocker; VIM, variability
independent of the mean.
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pressure was significantly weaker (P≤0.0021) in the ACEI
group (systolic/diastolic blood pressure: 4.6/2.8 mm Hg in
the morning and 7.0/4.0 mm Hg in the evening) than in the
CCB group (systolic/diastolic blood pressure: 8.3/
3.9 mm Hg in the morning and 9.4/4.5 mm Hg in the
evening) and the ARB group (systolic/diastolic blood pres-
sure: 8.2/4.5 mm Hg in the morning and 9.7/5.0 mm Hg in
the evening). In addition, the defined daily doses after first-
line drug prescription were significantly smaller in the ACEI
group compared with the other groups (P<0.0001). In
multivariable adjusted comparison, changes in VIM and ARV
based on morning home blood pressure did not differ among
the 3 drug classes (systolic: P≥0.057; diastolic P≥0.054). VIM
and ARV changes in evening measurement were also
essentially similar (P≥0.091) except for morning diastolic
ARV (P=0.012), which was largely reduced in the CCB group
(mean reduction of ARV: 0.213.87 mm Hg) compared with
ACEI (0.274.17 mm Hg) and ARB (0.034.14 mm Hg).
Results were confirmed when standard deviation and coeffi-
cient of variation were used as variability indexes instead of
VIM or ARV (Table 6).
Reduction of blood pressure level and variability were further
compared between patients with amlodipine (n=439) and other
CCBs (n=394) prescribed as the first-line drug (Table 7).
Amlodipine significantly lowered blood pressure level more
than other CCBs (systolic/diastolic blood pressure: 10.2/5.0
versus 6.0/2.7 mm Hg, respectively, in themorning and 11.3/
5.4 versus 7.4/3.5 mm Hg, respectively, in the evening;
P<0.0001), and this was confirmed by VIM and ARV calculated
by the morning systolic measurement (P≤0.018); however, VIM
and ARV derived from morning diastolic, evening systolic, and
evening diastolic measurements did not differ (P≥0.19).
Incidence of Events
Over a median follow-up of 7.3 years (interquartile range 4.8–
9.1 years; maximum 11.5 years), 61 patients died (3.62 per
1000 person-years), 43 (2.57 per 1000 person-years) expe-
rienced hard cardiovascular events, and 80 (4.84 per
1000 person-years) experienced broader cardiovascular
events. Considering cause-specific first cardiovascular events,
32 patients had stroke and 10 had myocardial infarction.
Table 8. Adjusted HRs for End Points in Relation to the Level and Variability of Blood Pressure at Baseline
End Point
Basic Model, BP Level Full Model, VIM Full Model, ARV
HR (95% CI) HR (95% CI) HR (95% CI)
Morning systolic measurement
Hard end point 1.67 (1.29–2.18)‡ 1.03 (0.76–1.39) 1.09 (0.81–1.45)
Composite CV event 1.44 (1.18–1.75)‡ 0.99 (0.81–1.22) 1.02 (0.82–1.26)
Total mortality 0.95 (0.72–1.24) 0.99 (0.77–1.28) 1.11 (0.87–1.41)
Morning diastolic measurement
Hard end point 1.48 (1.02–2.15)* 0.93 (0.67–1.29) 0.95 (0.73–1.24)
Composite CV event 1.38 (1.06–1.78)* 0.84 (0.66–1.08) 0.82 (0.67–1.01)
Total mortality 0.81 (0.60–1.10) 0.97 (0.75–1.24) 1.07 (0.84–1.36)
Evening systolic measurement
Hard end point 1.36 (1.03–1.79)* 1.31 (1.04–1.64)* 1.11 (0.87–1.43)
Composite CV event 1.32 (1.10–1.59)† 1.07 (0.88–1.29) 1.01 (0.83–1.22)
Total mortality 0.93 (0.71–1.20) 1.06 (0.83–1.35) 1.13 (0.89–1.43)
Evening diastolic measurement
Hard end point 1.30 (0.95–1.78) 1.25 (1.04–1.49)* 1.27 (1.06–1.53)*
Composite CV event 1.32 (1.07–1.63)† 1.14 (0.96–1.35) 1.17 (1.00–1.38)
Total mortality 0.91 (0.69–1.21) 1.01 (0.79–1.30) 1.09 (0.86–1.39)
Home blood pressure level and variability are based on self-measurement in the morning and in the evening for 3 to 5 days before treatment (average 4.95 and 4.93 days, respectively).
The numbers of patients with hard end points, composite CV events, and total mortality were 43, 80, and 61, respectively. The basic model includes in addition to blood pressure level, sex,
age, body mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of CV disease, and antihypertensive drug classes. Full
models include the aforementioned covariables plus VIM or ARV. HRs given with 95% CIs express the risk associated with a 1-SD increase in the explanatory variables. ARV indicates
average real variability; CV indicates cardiovascular; HR, hazard ratio; VIM, variability independent of the mean.
*P<0.05.
†P<0.01.
‡P<0.001.
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Outcomes in Relation to Blood Pressure Level
and Variability
In multivariable adjusted models (Table 8), the systolic
morning home blood pressure measured at baseline predicted
the hard cardiovascular end point (HR per 1-SD increment:
1.67; 95% CI 1.29–2.18; P=0.0001) and composite broader
cardiovascular events (HR 1.44; 95% CI 1.18–1.75;
P=0.0003), which were confirmatory with diastolic pressure
(P≤0.040). In models including morning blood pressure level,
morning VIM and ARV did not predict any cardiovascular
outcome (P≥0.056). Evening VIM in systolic and diastolic
blood pressures and evening ARV in diastolic blood pressure
significantly predicted future hard end points independent of
the mean level of evening blood pressure (P≤0.022). Level and
variability did not predict total mortality (P≥0.18).
HRs for end points in relation to mean and variability of
systolic and diastolic blood pressures measured during
monotherapy are shown in Table 9. In systolic measurements,
morning blood pressure was a significant predictor of hard
(HR 1.56; 95% CI 1.15–2.11, P=0.0041) and broader (HR
1.37; 95% CI 1.11–1.69; P=0.0029) cardiovascular events.
This was also the case with diastolic pressure and measure-
ments captured in the evening (P≤0.048). None of the
variability indexes, however, predicted cardiovascular end
points in models with blood pressure level, regardless of
morning or evening measurements after treatment initiation
(P≥0.22). Total mortality was not associated with blood
pressure information (P≥0.10).
Figures 2 and 3 illustrate the multivariable adjusted 10-
year risk of hard cardiovascular diseases in relation to the
mean level and VIM of morning and evening systolic blood
pressures measured at baseline (Figure 2) and after
monotherapy (Figure 3). Home blood pressure consistently
predicted cardiovascular events (P≤0.043). Evening home VIM
predicted hard cardiovascular diseases significantly
(P=0.043), independent of evening home blood pressure
level; however, VIM derived from morning measurement at
baseline was not a meaningful scale for hard cardiovascular
end points (P=0.86), and VIM captured during monotherapy
did not predict outcome (P≥0.54). As shown in Figure 4,
home evening ARV also predicted hard cardiovascular events
Table 9. Adjusted HRs for End Points in Relation to the Level and Variability of Blood Pressure After Monotherapy
End Point
Basic Model, BP Level Full Model, VIM Full Model, ARV
HR (95% CI) HR (95% CI) HR (95% CI)
Morning systolic measurement
Hard end point 1.56 (1.15–2.11)† 1.07 (0.82–1.41) 1.08 (0.80–1.44)
Composite CV event 1.37 (1.11–1.69)† 0.92 (0.74–1.14) 0.92 (0.73–1.14)
Total mortality 1.09 (0.85–1.39) 1.08 (0.84–1.38) 1.19 (0.96–1.49)
Morning diastolic measurement
Hard end point 1.55 (1.09–2.22)* 1.19 (0.90–1.57) 1.14 (0.87–1.50)
Composite CV event 1.32 (1.02–1.70)* 1.00 (0.77–1.30) 1.03 (0.82–1.29)
Total mortality 0.89 (0.67–1.20) 0.81 (0.61–1.07) 0.79 (0.59–1.05)
Evening systolic measurement
Hard end point 1.51 (1.18–1.92)‡ 1.10 (0.83–1.47) 1.10 (0.86–1.41)
Composite CV event 1.30 (1.08–1.56)† 1.03 (0.84–1.26) 1.05 (0.88–1.27)
Total mortality 1.22 (0.95–1.57) 0.94 (0.73–1.21) 0.96 (0.75–1.23)
Evening diastolic measurement
Hard end point 1.40 (1.03–1.91)* 1.00 (0.81–1.25) 1.11 (0.90–1.36)
Composite CV event 1.24 (1.00–1.54)* 0.91 (0.73–1.13) 0.99 (0.81–1.21)
Total mortality 1.15 (0.87–1.50) 0.96 (0.75–1.22) 0.97 (0.76–1.25)
Home blood pressure level and variability are based on self-measurement in the morning and in the evening for 3 to 5 days after the monotherapy (average 4.88 and 4.80 days,
respectively). The numbers of patients with hard end points, composite CV events, and total mortality were 43, 80, and 61, respectively. The basic model includes in addition to blood
pressure level, sex, age, body mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of CV disease, and antihypertensive
drug classes. Full models include the aforementioned covariables plus VIM or ARV. Results were confirmatory when defined daily doses of the monotherapy were further included in the
models. HRs given with 95% CIs express the risk associated with a 1-SD increase in the explanatory variables. ARV indicates average real variability; CV indicates cardiovascular; HR,
hazard ratio; VIM, variability independent of the mean.
*P<0.05.
†P<0.01.
‡P<0.001.
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(P=0.045), but morning ARV did not (P=0.55). Home ARV
under monotherapy had little impact on cardiovascular
outcome (P≥0.52) (Figure 5).
Discussion
Our study population comprised treatment-na€ıve or washout
patients on antihypertensive drugs at baseline; after inclusion,
they were followed up over a median of 7.3 years with
adjustment of antihypertensive drug treatment based on self-
measured home blood pressure. We investigated whether
blood pressure variability is influenced by antihypertensive
drug classes and adds to risk prediction beyond mean blood
pressure level. We found (1) that the effects of antihyperten-
sive drug therapy on blood pressure variability changes did
not differ; (2) that morning blood pressure variability at
baseline did not predict any outcomes in this population; (3)
that evening blood pressure variability captured at baseline
predicted hard cardiovascular end points independent of
blood pressure level; and (4) that blood pressure variability,
calculated 10 to 28 days after monotherapy started, had no
predictive power for cardiovascular events, regardless of
morning or evening measurement.
Recent studies suggest that stroke risk can be reduced
more effectively by targeting systolic blood pressure variabil-
ity along with blood pressure level using CCBs.24,25 Webb and
colleagues assessed the differences in home systolic blood
pressure variability from 3 to 10 days before to 8 to 15 days
after starting or increasing combinations of CCBs and
diuretics, renin and angiotensin system inhibitors, or both
drug classes among 288 patients with transient ischemic
attack or minor stroke.8 Home blood pressure were measured
3 times on 1 occasion and at 3 different times of day (ie,
awakening, midmorning, and before sleep). Day-to-day home
blood pressure variability was represented by the residual
coefficient of variation with a moving average of >5 days for
the mean of all clusters and the mean of clusters at each time
of day. Variability at 3 to 10 days before randomization was
similar for all clusters and for morning measurements
regardless of the 3 antihypertensive drug groups (P≥0.62),
whereas the residual coefficient of variation in patients with
CCBs and diuretics was significantly decreased when
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Figure 2. The 10-year estimated absolute risk of hard cardiovascular events associated with the mean
level of systolic home blood pressure and VIM in the morning (A) or the evening (B), measured at baseline.
The risk functions were standardized to the distribution (mean or ratio) of sex, age, body mass index,
corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of
cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43 hard cardiovascular
events occurred. Mean systolic blood pressure along the horizontal axis covers 135 to 170 mm Hg. Four
continuous lines represent the risk independently associated with VIM equal to 5, 8, 11, and 14 U. P values
are for the independent effect of systolic blood pressure (PSBP) and VIM (PVIM). VIM indicates variability
independent of the mean.
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compared with the other 2 groups (P≤0.015) at 8 to 15 days
after the intervention. Nevertheless, we are opposed to their
suggestion8,25,26 on the ground that the effect of antihyper-
tensive drug therapy on blood pressure variability changes did
not differ in this HOMED-BP population (n=2484). Our results
were based on precisely tracked information about antihy-
pertensive drug agents during treatment initiation. We
acknowledged that amlodipine significantly reduced morning
systolic VIM and ARV more than other CCBs (Table 7) (0.35
versus 0.14 U in VIM and 0.44 versus 0.65 mm Hg in
ARV; adjusted P≤0.018). Amlodipine is known to have a long
elimination half-life—34 hours, according to a review.26 This
long-acting effect may settle the variability of morning blood
pressure. Nevertheless, we would emphasize that at random-
ization, selection of a drug agent within a drug class (eg,
amlodipine or other CCBs within the CCB group) was based
entirely on the doctor’s judgment.10,13 Favorable effects of
amlodipine were reported during the HOMED-BP trial, for
example, a comparably powerful blood pressure–lowering
effect27 and a preventive effect for cardiovascular events28
that might be achieved by central blood pressure reduction.29
Consequently, we cannot eliminate the potential bias for the
judgment of amlodipine usage in the study population.
Changes in morning diastolic and evening systolic and
diastolic blood pressure variability indexes did not differ
(P≥0.19), and variability derived from the morning measure-
ment did not predict any outcomes before and after treatment
initiation (Tables 8 and 9). Those results suggest that
differences in antihypertensive drug classes regarding morn-
ing blood pressure variability have less impact in clinical
practice.
James was among those who observed the circadian
pattern of blood pressure regarding work stress.30,31 His team
investigated 110 normotensive young women aged
29.77.2 years who were employed at a hospital with a
day shift.31 Along with ambulatory blood pressure monitoring,
each woman self-rated her perceived stress in work and home
environments. Women who perceived greater stress at work
had significantly higher blood pressure at work than women
who perceived equal or greater stress at home (123 versus
115 mm Hg systolic and 78 versus 74 mm Hg diastolic,
P<0.01), whereas no significant differences in pressures were
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Figure 3. The 10-year estimated absolute risk of hard cardiovascular events associated with the mean
level of systolic home blood pressure and VIM in the morning (A) or the evening (B), measured after
monotherapy. The risk functions were standardized to the distribution (mean or ratio) of sex, age, body
mass index, corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes
mellitus, history of cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43
hard cardiovascular events occurred. Mean systolic blood pressure along the horizontal axis covers 125 to
160 mm Hg. Four continuous lines represent the risk independently associated with VIM equal to 5, 8, 11,
and 14 U. P values are for the independent effect of systolic blood pressure (PSBP) and VIM (PVIM). VIM
indicates variability independent of the mean.
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measured in the home environment between the 2 groups.
These effects were independent of weight, age, and menstrual
cycle. James et al suggested that the perception of stress has
a significant effect on the circadian pattern of blood pressure
variation.31 Although it should not be pushed so far, instability
of blood pressure in the late evening may reflect the diversity
of daily activities, and the introduction of antihypertensive
drug treatment can preclude residual impact of instability,
resulting in the disappearance of differences of prognostic
impact on blood pressure variability after the treatment
initiated in the present patients.
Our current study must be interpreted within the context of
several potential limitations. First, because the patients in
HOMED-BP received home blood pressure–guided therapy,10
treatment was adjusted according to self-measured home
blood pressure level, not variability. Second, we based our
analyses on only a single blood pressure reading in the
morning and the evening over 5 days; there were 5 consec-
utive home blood pressure readings in a European study
population32 and readings over 7 days in the Finn-Home
study6 and a median of 26 days in the Ohasama study.5
Regarding the home blood pressure level, we reported that
even a single measurement is a potent predictor of stroke
both in the morning33 and the evening,34 and a longer period
of measurement could increase diagnostic accuracy.33–35
Little information, however, is available on how many days are
required to capture blood pressure variability in a reliable way.
Third, we excluded 1034 of the original 3518 randomized
patients. Although baseline characteristics were balanced
properly, randomization might not be a given in this post hoc
analysis. Fourth, we measured home blood pressure with an
upper arm cuff oscillometric device,14 which could not
capture information on central blood pressure. Blood pressure
variability based on central blood pressure might have
different prognostic significance. Finally, although our results
are representative for health care provided to middle-aged
and older Japanese participants, they might not be applicable
to other settings or ethnic groups with different distributions
of risk factors.
Perspectives
We found that the independent prognostic significance of
home blood pressure variability was derived from evening
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Figure 4. The 10-year estimated absolute risk of hard cardiovascular events associated with the mean
level of systolic home blood pressure and ARV in the morning (A) or the evening (B), measured at baseline.
The risk functions were standardized to the distribution (mean or ratio) of sex, age, body mass index,
corresponding heart rate, current smoking and drinking, hypercholesterolemia, diabetes mellitus, history of
cardiovascular disease, and antihypertensive drug classes. Among 2484 patients, 43 hard cardiovascular
events occurred. Mean systolic blood pressure along the horizontal axis covers 135 to 170 mm Hg. Four
continuous lines represent the risk independently associated with ARV equal to 6, 9, 12, and 15 mm Hg. P
values are for the independent effect of systolic blood pressure (PSBP) and ARV (PARV). ARV indicates
average real variability.
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systolic pressure before treatment allocation; however, we
were unable to modify blood pressure variability consciously
by choosing a drug class of antihypertensive agents, at least
among CCBs, ACEIs, and ARB, according to the current
findings. Blood pressure variability derived from morning
home blood pressure did not substantially refine risk profiling
beyond the blood pressure level. Consequently, we emphasize
that home blood pressure level is the predominant risk factor
and should remain the primary focus for risk stratification and
treatment in clinical practice because home blood pressure is
manageable by lifestyle modifications and adequate antihy-
pertensive drug treatment.10 Nevertheless, we may deal with
evening home blood pressure variability as the independent
risk factor, not as the treatment target but rather for
assessment of the comprehensive cardiovascular disease
risk.
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